Reply
Raul Lazaro, Raymond Wu, Hidekazu Tsukamoto – 9 October 2014
Differential osteopontin functions: The role of osteopontin isoforms
Jason D. Coombes, Wing‐Kin Syn – 9 October 2014
Interleukin‐1β/Iinterleukin‐1 receptor‐associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis
Bo Su, Tao Luo, Junjie Zhu, Jing Fu, Xiaofang Zhao, Lei Chen, Huilu Zhang, Yibin Ren, Lexing Yu, Xiaojun Yang, Mengchao Wu, Gensheng Feng, Shao Li, Yao Chen, Hongyang Wang – 7 October 2014 – Hepatocellular carcinoma (HCC) is a prototype of inflammation‐associated cancer. Oncoprotein Gankyrin, which mostly increases in HCC, plays a critical role in HCC development and metastasis. However, the exact mechanism of Gankyrin up‐regulation in HCC remains unclear.
Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle
Peter G. Stock, Norah A. Terrault – 7 October 2014
Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle
Peter G. Stock, Norah A. Terrault – 7 October 2014
Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis
Gwilym J. Webb, Gideon M. Hirschfield – 7 October 2014
Treatment of PD‐1−/− mice with amodiaquine and anti‐CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients
Imir G. Metushi, M. Anthony Hayes, Jack Uetrecht – 6 October 2014 – The mechanism of idiosyncratic drug‐induced liver injury (IDILI) remains poorly understood, to a large degree because of the lack of a valid animal model. Recently, we reported an animal model in which treatment of female C57BL/6 mice with amodiaquine (AQ) resulted in mild liver injury with a delayed onset and resolution despite continued treatment. Such adaptation is a common outcome in the IDILI caused by drugs that can cause liver failure.
Local allograft irradiation as an adjunct for treating severe resistant rejection after liver transplantation in adults
Rajesh Ramanathan, Amit Sharma, Matthew Kaspar, Martha Behnke, Shiyu Song, R. Todd Stravitz, Adrian Cotterell, Marc Posner, Robert A. Fisher – 6 October 2014 – Acute rejection after liver transplantation occurs in one‐third of all recipients and can be managed with conventional rejection therapy in the majority of cases. In rare instances, patients with severe acute rejection may be refractory to or have contraindications for conventional therapies.
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study
Filipe Nery, Sylvie Chevret, Bertrand Condat, Emmanuelle de Raucourt, Larbi Boudaoud, Pierre‐Emmanuel Rautou, Aurelie Plessier, Dominique Roulot, Cendrine Chaffaut, Valerie Bourcier, Jean‐Claude Trinchet, Dominique‐Charles Valla, on behalf of Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire – 6 October 2014 – In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence of the progression of liver disease.
Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma
Chunping Wang, Huaming Wang, Wuwei Yang, Kaiwen Hu, Hui Xie, Ke‐Qin Hu, Wenlin Bai, Zheng Dong, Yinying Lu, Zhen Zeng, Min Lou, Hong Wang, Xudong Gao, Xiujuan Chang, Linjing An, Jianhui Qu, Jin Li, Yongping Yang – 6 October 2014 – Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment.